Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03432741
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:45.454391+00:00
Published At
2025-05-26T00:00:00+00:00
Record Updated At
2025-05-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Breast Adenocarcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Breast Carcinoma", "Refractory Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Breast Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-05-26"
protocolSection.identificationModule.nctId
"NCT03432741"
protocolSection.identificationModule.officialTitle
"Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Breast Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mycosis Fungoides (protocolSection.conditionsModule.conditions)
  • Refractory Nodal Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.